bufuralol has been researched along with midazolam in 22 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.55) | 18.2507 |
2000's | 12 (54.55) | 29.6817 |
2010's | 8 (36.36) | 24.3611 |
2020's | 1 (4.55) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Kanebratt, KP; Sjögren, E; Svanberg, P | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Bonnabry, P; Dayer, P; Leemann, T | 1 |
Fujita, K; Kamataki, T; Nakayama, K; Nohmi, T; Tsuruma, K; Yamada, M; Yamazaki, Y | 1 |
Chiba, K; Kobayashi, K; Shimada, N; Urashima, K | 1 |
Kokue, E; Kuroha, M; Kuze, Y; Shimoda, M | 1 |
Beattie, IG; Graham, KS; Riley, RJ; Weaver, R | 1 |
DeSante, KA; Gillespie, JS; Jensen, CB; Long, AJ; Petullo, D; Read, HA; Ring, B; Sanburn, NP; Sauer, JM; Smith, BP; VandenBranden, MR; Witcher, JW; Wrighton, SA | 1 |
Kokue, E; Kuroha, M; Shibata, Y; Shimoda, M; Zhang, K | 1 |
Heim, J; Jensen, NS; Li, L; Pan, RM; Porter, TD; Ring, B; Russo, G; Silber, P; Tine, JA; Wedlund, PJ | 1 |
Carter, GT; Di, L; Kerns, EH; Li, SQ | 1 |
Regmi, NL; Sanda, S; Sasaki, K; Shah, SS; Shimoda, M | 1 |
Hall, SD; Harrelson, JP; Mao, J; Mohutsky, MA; Wrighton, SA | 1 |
Furue, MK; Hayakawa, T; Higuchi, M; Inamura, M; Kawabata, K; Kikuchi, K; Mizuguchi, H; Nagamoto, Y; Sakurai, F; Sugawara, M; Takayama, K; Tashiro, K; Watanabe, H | 1 |
Chen, Y; Subramanian, R; Zhu, X | 1 |
Gaudette, F; Huguet, J; Michaud, V; Turgeon, J | 1 |
Andersson, TB; Artursson, P; Christensen, H; Krogstad, V; Matsson, P; Urdzik, J; Wegler, C | 1 |
1 trial(s) available for bufuralol and midazolam
Article | Year |
---|---|
Effect of oral administration of clinically relevant doses of dexamethasone on regulation of cytochrome P450 subfamilies in hepatic microsomes from dogs and rats.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Cytochrome P-450 Enzyme System; Dexamethasone; Dogs; Ethanolamines; Hypnotics and Sedatives; Hypoglycemic Agents; Male; Microsomes, Liver; Midazolam; Oxazines; Rats; Rats, Wistar; Tolbutamide | 2006 |
21 other study(ies) available for bufuralol and midazolam
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
Topics: Chromatography, Liquid; Cytochrome P-450 Enzyme System; Humans; Kinetics; Microsomes, Liver; Research Design; Tandem Mass Spectrometry | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Topics: Carbon Monoxide; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; Ethanolamines; Humans; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Oxidoreductases, O-Demethylating | 1994 |
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Topics: Alkylating Agents; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Ethanolamines; Genetic Engineering; Humans; Midazolam; Mixed Function Oxygenases; Mutagenicity Tests; NADP; NADPH-Ferrihemoprotein Reductase; Nitrosamines; Recombinant Proteins; Salmonella typhimurium; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Baculoviridae; Cells, Cultured; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Gene Expression; Humans; Insecta; Isoenzymes; Mephenytoin; Midazolam; Nitrophenols; Pharmaceutical Preparations; Phenacetin; Rats; Substrate Specificity; Testosterone; Tumor Cells, Cultured | 2002 |
In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes.
Topics: Animals; Antifungal Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; Ethanolamines; Isoenzymes; Ketoconazole; Kinetics; Male; Microsomes, Liver; Midazolam; Oxazines; Tolbutamide | 2002 |
Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Industry; Drug Interactions; Drugs, Investigational; Escherichia coli; Ethanolamines; Evaluation Studies as Topic; Kinetics; Mass Spectrometry; Mephenytoin; Microsomes, Liver; Midazolam; Molecular Probes; Phenacetin; Recombinant Proteins; Substrate Specificity | 2003 |
Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Topics: Aryl Hydrocarbon Hydroxylases; Atomoxetine Hydrochloride; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Diclofenac; Drug Interactions; Ethanolamines; Humans; Hydroxylation; Microsomes, Liver; Midazolam; Phenacetin; Propylamines | 2004 |
New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Topics: Alleles; Base Sequence; Cryopreservation; Cytochrome P-450 CYP2D6; Ethanolamines; Genotype; Hepatocytes; Humans; In Vitro Techniques; Microsomes, Liver; Midazolam; Molecular Sequence Data; Phenotype | 2006 |
Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Fluorescent Dyes; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Midazolam; Recombinant Proteins; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Substrate Specificity; Tandem Mass Spectrometry | 2007 |
Characterization of cytochrome P450-mediated drug metabolism in cats.
Topics: Adrenergic beta-Antagonists; Animals; Cats; Cytochrome P-450 Enzyme System; Ethanolamines; Female; Hypnotics and Sedatives; Hypoglycemic Agents; Male; Microsomes, Liver; Midazolam; Oxazines; Tolbutamide | 2007 |
Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Topics: Aryl Hydrocarbon Hydroxylases; Cell Culture Techniques; Cells, Cultured; Chromatography, High Pressure Liquid; Cryopreservation; Culture Media; Culture Media, Serum-Free; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Hepatocytes; Humans; Hydroxylation; Midazolam; Plasma; Predictive Value of Tests; Substrate Specificity; Tandem Mass Spectrometry | 2012 |
Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1α transduction.
Topics: Bupropion; Cell Differentiation; Cell Line; Embryonic Stem Cells; Ethanolamines; Gene Transfer Techniques; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 3-beta; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Midazolam; Paclitaxel; Phenacetin; Testosterone; Tolbutamide; Transduction, Genetic | 2012 |
Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Topics: Algorithms; Animals; Biotransformation; Chlorpromazine; Chromatography, High Pressure Liquid; Ethanolamines; Microsomes, Liver; Midazolam; Oxidation-Reduction; Quinidine; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes.
Topics: Bupropion; Butyrophenones; Carbamates; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Ethanolamines; Humans; Lauric Acids; Microsomes; Midazolam; Myocardium; Oxazines; Piperidines; Tolbutamide | 2019 |
Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.
Topics: Bupropion; Cytochrome P-450 Enzyme System; Diclofenac; Drug Evaluation, Preclinical; Ethanolamines; Hepatobiliary Elimination; Hepatocytes; Humans; Liver; Microsomes, Liver; Midazolam; Omeprazole; Proteome; Proteomics | 2021 |